[Skip to Navigation]
Comment & Response
January 29, 2020

Concerns About the HCM Risk-Kids Study

Author Affiliations
  • 1Hypertrophic Cardiomyopathy Center and Research Institute, Division of Cardiology, Tufts Medical Center, Boston, Massachusetts
JAMA Cardiol. 2020;5(3):362-363. doi:10.1001/jamacardio.2019.5786

To the Editor We are hypertrophic cardiomyopathy (HCM) investigators with a major investment in strategies for the prevention of sudden death (SD) using implantable cardioverter-defibrillators (ICDs).1 In this regard, we read with interest the recent large multicenter European study from Norrish et al2 addressing risk stratification and selection of young patients with HCM for ICDs.

Add or change institution